-
Abbisko Therapeutics to Present CSF-1R Inhibitor ABSK021 Data at CTOS Annual Meeting
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it will present data from two clinical studies on its next-generation CSF-1R inhibitor, ABSK021 (pimicotinib), at the Connective Tissue Oncology Society (CTOS) annual meeting. The presentations will highlight significant findings from the Phase Ib clinical study and the ongoing…
-
Ascentage Pharma’s Olverembatinib Showcases Promising Results at ASH Annual Meeting
•
Suzhou-based Ascentage Pharma (HKG: 6855) has presented the latest results of multiple studies regarding its innovative drug candidate olverembatinib at the 65th American Society of Hematology (ASH) annual meeting. The data highlights the potential of olverembatinib in treating various hematological malignancies, including chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic…
-
Sino Medical Sciences Technology Secures TFDA Approval for HT Supreme Drug-Eluting Stent System
•
Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that it has received market approval from the Taiwan Food and Drug Administration (TFDA) for its HT Supreme drug-eluting stent system. This significant milestone marks the company’s expansion into the Taiwan market with a cutting-edge drug-device…
-
Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has received approval from the National Medical Products Administration (NMPA) to commence a Phase I clinical study for its proprietary B019 injection. B019 is a chimeric antigen receptor (CAR) autologous T cell injection that targets CD19…
-
I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA
•
China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for their CD38 monoclonal antibody (mAb), felzartamab. This designation highlights the drug’s potential as a treatment for primary membranous nephropathy (PMN), a rare…
-
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
•
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio…
-
Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales
•
US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023, showing a 1% year-on-year (YOY) decrease in sales to USD 1.519 billion in constant currency terms. The company’s performance was marked by a 7% decline in Women’s Health sales to USD 418 million, a 10%…
-
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third quarter of 2023, reporting a contraction of -41% year-on-year (YOY) in operational terms to USD 13.2 billion, excluding foreign currency fluctuations. The quarter was marked by a net loss of USD 2.38 billion, the company’s…
